The first patient has been dosed with a vaccine for the tropical disease schistosomiasis, developed by Seattle biotech company PAI Life Sciences. Darrick Carter, professor of global health, was mentioned.
PAI Life Sciences, a biotechnology company specializing in translational research for neglected tropical diseases, today announced the dosing of the first healthy volunteer in a clinical trial of SchistoShield®, the company’s preventive vaccine against schistosomiasis, a major tropical disease threatening nearly 1 billion people in 79 countries with more than 260 million people currently infected. Darrick Carter, professor of global health, was mentioned.
More than 2.7 billion people live in areas where the Zika Virus may soon spread, with potentially devastating effects for infants born in those areas. In response, faculty from across the University of Washington are working to stop the spread and effects of the Zika virus using a variety of approaches and disciplines. Here are some examples of their work, some of which is funded and some of which has not yet been funded.